Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA269303 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:We previously identified endothelial cell-selective adhesion molecule (ESAM) as a novel functional marker of hematopoietic stem cells (HSCs) in mice. To examine ESAM expression in human, we analyzed diverse HSC sources using flow cytometry. From mononuclear cells of collagenase-treated human hip bones, we obtained two ESAM positive populations in CD34(+) CD38(-) fraction, referred to as ESAM(High) and ESAM(Bright). Then we conducted microarray analyses comparing gene expression signatures between these two populations. Trabecular tissues of the femora were treated with collagenase IV and DNase. Mononuclear cells were collected, and CD34(+) CD38(-) ESAM(High) or ESAM(Bright) cells were sorted.
2014-12-05 | E-GEOD-63877 | biostudies-arrayexpress
Project description:We previously identified endothelial cell-selective adhesion molecule (ESAM) as a novel functional marker of hematopoietic stem cells (HSCs) in mice. To examine ESAM expression in human, we analyzed diverse HSC sources using flow cytometry. From mononuclear cells of collagenase-treated human hip bones, we obtained two ESAM positive populations in CD34(+) CD38(-) fraction, referred to as ESAM(High) and ESAM(Bright). Then we conducted microarray analyses comparing gene expression signatures between these two populations.
2014-12-05 | GSE63877 | GEO
Project description:Cord blood (CB) samples from normal donors were obtained with informed consent. Fresh CB samples were processed within 18-34h after collection. Mononuclear cells were isolated and CD34+ fraction was separated. CB CD34+ enriched fraction was lineage depleted by staining with purified anti-human CD2, CD3, CD4, CD7, CD8a, CD11b, CD14, CD19, CD20, CD56, CD235a followed by Qdot 605 conjugated goat F(ab')2 anti-mouse IgG (H+L). Cells were also stained with anti-human CD38-FITC, CD45RA-PE or -BV650, CD123-PE Cy7, CD90-biotin, CD34- PerCP and CD10-APC. Finally, cells were incubated with streptavidin-conjugated APC-eF780 and Hoechst 33258 (Invitrogen, final concentration: 1 g/ml). Populations were defined, as follows: HSC - Lin-CD34+CD38-CD90+CD45RA-CD10-, MPP - Lin-CD34+CD38-CD90-CD45RA-CD10-, LMPP - Lin-CD34+CD38-CD90-/loCD45RA+CD10-, MLP - Lin-CD34+CD38-CD90-/loCD45RA+CD10+, GMP - Lin-CD34+CD38+CD123+CD45RA+CD10-, CMP - Lin-CD34+CD38+CD123+CD45RA-CD10-, MEP - Lin-CD34+CD38+CD123-CD45RA-CD10-.
2017-10-03 | E-MTAB-5456 | biostudies-arrayexpress
Project description:Comparison of the CD34+CD38- versus CD34+CD38+ fractions of human umbilical cord blood and comparison of the slow-dividing fraction versus the fast dividing fraction of the CD34+/CD38- population.
2005-09-08 | E-EMBL-1 | biostudies-arrayexpress
Project description:Leukemic stem cells (LSC) might be the source for leukemic disease self-renewal and account for disease relapse after treatment, which makes them a critical target for further therapeutic options. Leukemia associated antigens (LAA) might be suitable structures to be attacked by immunotherapeutic agents. We performed primary AML sample enrichment and microarray studies to define LAA expression levels in AML. We compared the LAA expression in the enriched CD34+CD38- AML fraction to that of enriched HSC of healthy donors and AML bulk cells (CD34+CD38+, CD34-CD38+ and CD34-CD38). Furthermore, we investigated the expression patterns of co-stimulatory molecules in LSC, bulk AML cells and enriched HSC, Conclusion: We demonstrated the differential expression of several LAA in LSC, and their suitability as target structures. We enriched primary AML samples using CD34 and CD38 as markers to compare LAA expression levels of LSC, HSC and AML bulk.
2015-04-23 | GSE68172 | GEO
Project description:The t(8;21) Acute Myeloid Leukaemia (AML) Kasumi-1cell line with N822K KIT mutation, is a model system for leukemogenesis. As AML initiating cells reside in the CD34+CD38- fraction, we addressed the refined cytogenomic characterization and miRNA expression of Kasumi-1 cell line and its FACS-sorted subpopulations focussing on this compartment. By conventional cytogenetics, Spectral Karyotyping and array-CGH the cytogenomic profile of Kasumi-1 cells evidenced only subtle regions differentially represented in CD34+CD38- cells. Expression profiling by a miRNA platform showed a set of miRNA differentially expressed in paired subpopulations and the signature of miR-584 and miR-182 upregulation in the CD34+CD38- fraction.
2010-02-19 | E-TABM-909 | biostudies-arrayexpress
Project description:To determine the molecular mechanisms involved in the compromised erythropoiesis of ESAM-KO mice, Lin- FCgRII/III-/Lo CD41Lo c-Kit+ Sca1- endoglin+ CD150+ cells, which contain mostly BFU-E and CFU-E, were sorted from 5-FU-treated WT and ESAM-KO mice, and were subjected to microarray analyses.
2016-04-26 | GSE73496 | GEO
Project description:We demonstrated that the induction of BAZ2B expression in human CD34+ cells or Lineage-CD34+CD38+ cells, enhanced the stemness of clonogenicity of the cells in in vitro assays. In order to confirm the stemness mRNA expression signature of the progenitors we performed single-cell sequencing of the BAZ2B-treated CD34+ or Lineage-CD34+CD38+ progenitors and used the luciferase-treated progenitors as a control.
2020-11-12 | GSE114239 | GEO
Project description:In an attempt to identify novel markers and immunologic targets in leukemic stem cells (LSC) in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), we screened samples of patients with AML, CML, and controls for expression of cell surface antigens on CD34+/CD38− and CD34+/CD38+ cells by multi-color flow cytometry. In addition, we examined mRNA expression profiles in highly purified CD34+/CD38− and CD34+/CD38+ cells by gene array- and qPCR analyses. Aberrantly expressed markers were identified in all patient cohorts examined.
2020-09-21 | GSE138883 | GEO
Project description:Leukemic stem cells (LSC) might be the source for leukemic disease self-renewal and account for disease relapse after treatment, which makes them a critical target for further therapeutic options. Leukemia associated antigens (LAA) might be suitable structures to be attacked by immunotherapeutic agents. We performed primary AML sample enrichment and microarray studies to define LAA expression levels in AML. We compared the LAA expression in the enriched CD34+CD38- AML fraction to that of enriched HSC of healthy donors and AML bulk cells (CD34+CD38+, CD34-CD38+ and CD34-CD38). Furthermore, we investigated the expression patterns of co-stimulatory molecules in LSC, bulk AML cells and enriched HSC, Conclusion: We demonstrated the differential expression of several LAA in LSC, and their suitability as target structures. We enriched primary AML samples using CD34 and CD38 as markers to compare LAA expression levels of LSC, HSC and AML bulk. LAA expression profiles comparing LSC, HSC and leukemic bulk AML citation: Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens Vanessa Schneider, Lu Zhang, Markus Rojewski, Natalie Fekete, Hubert Schrezenmeier, Alexander Erle, Lars Bullinger, Susanne Hofmann, Marlies Götz, Konstanze Döhner, Susann Ihme, Hartmut Döhner, Christian Buske, Michaela Feuring-Buske, Jochen Greiner
2015-04-23 | E-GEOD-68172 | biostudies-arrayexpress